Biotech Insider Selling: Gilead Sciences (NASDAQ:GILD), Incyte Corporation (NASDAQ:INCY), Sangamo Biosciences (NASDAQ:SGMO), Jazz Pharmaceuticals – Ordinary Shares (NASDAQ:JAZZ), Portola Pharmaceuticals. (NASDAQ:PTLA)

Gilead Sciences Inc. (NASDAQ:GILD) Director John Francis Cogan unloaded 5,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $81.82, for a total value of $409,100.00. Following the sale, the director now directly owns 42,405 shares in the company, valued at approximately $3,469,577. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 2.93%. On last trading day company shares ended up $81.80. Analysts mean target price for the company is $100.57. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 3.92%.

Incyte Corporation (NASDAQ:INCY) EVP James M. Daly sold 11,111 shares of Incyte stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $56.03, for a total value of $622,549.33.Incyte Corporation (NASDAQ:INCY) shares advanced 0.81% in last trading session and ended the day on $56.22. INCY gross Margin is 99.80% and its return on assets is -23.60%.Incyte Corporation (NASDAQ:INCY) quarterly performance is 8.64%.

Sangamo Biosciences Inc. (NASDAQ:SGMO) CEO Edward O. Lanphier II unloaded 25,000 shares of Sangamo Biosciences stock on the open market in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $16.41, for a total transaction of $410,250.00. Following the transaction, the chief executive officer now directly owns 295,000 shares in the company, valued at approximately $4,840,950. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares moved down -1.60% in last trading session and was closed at $15.40, while trading in range of $15.02 – $15.84. Sangamo Biosciences, Inc. (NASDAQ:SGMO) year to date (YTD) performance is 10.87%.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) EVP Fintan Keegan sold 3,750 shares of Jazz Pharmaceuticals plc – stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $150.00, for a total value of $562,500.00. Following the completion of the sale, the executive vice president now directly owns 33,272 shares in the company, valued at approximately $4,990,800. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) ended the last trading day at $150.42. Company weekly volatility is calculated as 3.54% and price to cash ratio as 35.57.Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) showed a negative weekly performance of -1.06%.

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) CFO Mardi Dier sold 3,706 shares of the company’s stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $29.95, for a total transaction of $110,994.70. Following the completion of the sale, the chief financial officer now directly owns 16,118 shares in the company, valued at approximately $482,734.Portola Pharmaceuticals Inc. (NASDAQ:PTLA) weekly performance is -6.39%. On last trading day company shares ended up $28.43. Analysts mean target price for the company is $38.50. Portola Pharmaceuticals Inc. (NASDAQ:PTLA) distance from 50-day simple moving average (SMA50) is 19.65%.